The challenges for cancer chemoprevention

被引:60
作者
Penny, Lewis K. [1 ]
Wallace, Heather M. [1 ]
机构
[1] Univ Aberdeen, Sch Med Med Sci & Nutr, Aberdeen, Scotland
关键词
HUMAN-PAPILLOMAVIRUS TYPE-16; SURGICAL ADJUVANT BREAST; HIGH-RISK; HELICOBACTER-PYLORI; CARDIOVASCULAR EVENTS; POSTMENOPAUSAL WOMEN; COLORECTAL ADENOMAS; GASTRIC-CANCER; DOUBLE-BLIND; PREVENTION;
D O I
10.1039/c5cs00705d
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The incidence of cancer is rising in parallel with an ageing populous thus increasing the strain on both treatment options and budgets for healthcare providers worldwide. New cancer therapies are being developed but at what cost? The new treatments are expensive and poor survival rates still exist for some cancers. What is needed now is to prevent or at least limit the disease occurring in the first place. This review evaluates the current situation and the progress in upcoming strategies as well as suggesting some areas for further research within the increasingly important field of cancer chemoprevention. The key principles of cancer chemoprevention are discussed and areas for improvement highlighted. Despite significant progress, chemoprevention has not been widely adopted. Cancer chemoprevention has many challenges to face but this only emphasises the size of the task. These hurdles include a lack of awareness of the benefits, a lack of interest and a lack of investment in taking prevention forward. Despite the huge potential importance of cancer prevention and clinical success stories such as the well-publicised HPV vaccine, the challenges remain significant. With cancer and its treatment being a global issue, the opportunities offered by chemoprevention must be re-evaluated and uptake of chemoprevention actively encouraged. If chemoprevention is to be adopted successfully, a holistic approach is required. This approach will involve multidisciplinary teams of healthcare providers and scientists with the big challenge particularly for medicinal chemists being to design and synthesise the ideal chemopreventative agent.
引用
收藏
页码:8836 / 8847
页数:12
相关论文
共 80 条
  • [1] The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts
    Abboud, Camille
    Berman, Ellin
    Cohen, Adam
    Cortes, Jorge
    DeAngelo, Daniel
    Deininger, Michael
    Devine, Steven
    Druker, Brian
    Fathi, Amir
    Jabbour, Elias
    Jagasia, Madan
    Kantarjian, Hagop
    Khoury, Jean
    Laneuville, Pierre
    Larson, Richard
    Lipton, Jeffrey
    Moore, Joseph O.
    Mughal, Tariq
    O'Brien, Susan
    Pinilla-Ibarz, Javier
    Quintas-Cardama, Alfonso
    Radich, Jerald
    Reddy, Vishnu
    Schiffer, Charles
    Shah, Neil
    Shami, Paul
    Silver, Richard T.
    Snyder, David
    Stone, Richard
    Talpaz, Moshe
    Tefferi, Ayalew
    Van Etten, Richard A.
    Wetzler, Meir
    Abruzzese, Elisabetta
    Apperley, Jane
    Breccia, Massimo
    Byrne, Jenny
    Cervantes, Francisco
    Chelysheva, Ekaterina
    Clark, R. E.
    de Lavallade, Hugues
    Dyagil, Iryna
    Gambacorti-Passerini, Carlo
    Goldman, John
    Haznedaroglu, Ibrahim
    Hjorth-Hansen, Henrik
    Holyoake, Tessa
    Huntly, Brian
    le Coutre, Philipp
    Lomaia, Elza
    [J]. BLOOD, 2013, 121 (22) : 4439 - 4442
  • [2] Aluyen Julia Khristine, 2012, Journal of Dietary Supplements, V9, P45, DOI 10.3109/19390211.2011.650842
  • [3] Berlin JM, 2008, J DRUGS DERMATOL, V7, P669
  • [4] Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial
    Bresalier, RS
    Sandler, RS
    Quan, H
    Bolognese, JA
    Oxenius, B
    Horgan, K
    Lines, C
    Riddell, R
    Morton, D
    Lanas, A
    Konstam, MA
    Baron, JA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) : 1092 - 1102
  • [5] MENOPAUSAL ESTROGENS AND BREAST-CANCER RISK - AN EXPANDED CASE-CONTROL STUDY
    BRINTON, LA
    HOOVER, R
    FRAUMENI, JF
    [J]. BRITISH JOURNAL OF CANCER, 1986, 54 (05) : 825 - 832
  • [6] Forecasting individual breast cancer risk using plasma metabolomics and biocontours
    Bro, Rasmus
    Kamstrup-Nielsen, Maja H.
    Engelsen, Soren Balling
    Savorani, Francesco
    Rasmussen, Morten A.
    Hansen, Louise
    Olsen, Anja
    Tjonneland, Anne
    Dragsted, Lars Ove
    [J]. METABOLOMICS, 2015, 11 (05) : 1376 - 1380
  • [7] Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial
    Burn, John
    Gerdes, Anne-Marie
    Macrae, Finlay
    Mecklin, Jukka-Pekka
    Moeslein, Gabriela
    Olschwang, Sylviane
    Eccles, Diane
    Evans, D. Gareth
    Maher, Eamonn R.
    Bertario, Lucio
    Bisgaard, Marie-Luise
    Dunlop, Malcolm G.
    Ho, Judy W. C.
    Hodgson, Shirley V.
    Lindblom, Annika
    Lubinski, Jan
    Morrison, Patrick J.
    Murday, Victoria
    Ramesar, Raj
    Side, Lucy
    Scott, Rodney J.
    Thomas, Huw J. W.
    Vasen, Hans F.
    Barker, Gail
    Crawford, Gillian
    Elliott, Faye
    Movahedi, Mohammad
    Pylvanainen, Kirsi
    Wijnen, Juul T.
    Fodde, Riccardo
    Lynch, Henry T.
    Mathers, John C.
    Bishop, D. Timothy
    [J]. LANCET, 2011, 378 (9809) : 2081 - 2087
  • [8] CDC, HUM PAP HPV VACC SAF
  • [9] Randomized Phase II Trial of Lyophilized Strawberries in Patients with Dysplastic Precancerous Lesions of the Esophagus
    Chen, Tong
    Yan, Fei
    Qian, Jiaming
    Guo, Mingzhou
    Zhang, Hongbing
    Tang, Xiaofei
    Chen, Fang
    Stoner, Gary D.
    Wang, Xiaomin
    [J]. CANCER PREVENTION RESEARCH, 2012, 5 (01) : 41 - 50
  • [10] Identification of aspirin analogues that repress NF-κB signalling and demonstrate anti-proliferative activity towards colorectal cancer in vitro and in vivo
    Claudius, Ann-Katrin
    Kankipati, Chandra S.
    Kilari, Rajagopal S.
    Hassan, Sadiya
    Guest, Kerry
    Russell, Steven T.
    Perry, Chris J.
    Stark, Lesley A.
    Nicholl, Iain D.
    [J]. ONCOLOGY REPORTS, 2014, 32 (04) : 1670 - 1680